0001850079falseTelesis Bio Inc.00018500792024-08-072024-08-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 07, 2024

 

 

TELESIS BIO INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40497

45-1216839

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10431 Wateridge Circle

Suite 150

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 228-4115

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TBIO

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On August 7, 2024, Telesis Bio Inc. issued a press release (the “Earnings Release”) announcing results for the quarter ended June 30, 2024. A copy of the Earnings Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

The information under Item 2.02 in this current report on Form 8-K and the related information in the Earnings Release attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated August 7, 2024

104

Cover Page Interactive Data File (formatted as Inline XBRL)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TELESIS BIO INC.

 

 

 

 

Date:

August 7, 2024

By:

/s/ Eric Esser

 

 

 

Eric Esser
President and Chief Executive Officer

 


Exhibit 99.1

img44325073_0.jpg 

 

Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

 

August 7, 2024

SAN DIEGO, August 7, 2024 (GLOBE NEWSWIRE) – Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024.

 

Highlights

Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company’s presentation “Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneering on-Demand DNA and mRNA Synthesis for Biotechnological Innovation”, delivered in May at the 2024 PEGS conference in Boston was well received, and the Company continues to see growing interest in the market for adopting this platform.
Eton Subsidiary – the Company made a strategic decision to divest its Eton subsidiary. As a result, Eton is reflected as a discontinued operation in the consolidated financial statements of the Company for all periods presented.
Second Quarter, 2024 Restructuring – along with the action related to our Eton subsidiary noted above, in the second quarter of the year the Company undertook a variety of additional restructuring activities tied to further reducing its cost base across all areas of the business. The goal of this process was to align our cost structure to current market conditions and our focus on commercial adoption of Gibson SOLA. While these actions resulted in significant second quarter, 2024 non-recurring expenditures (described in the Summary of Financial Results that follows), the favorable impact on future quarters will be substantial relative to Company spending levels of recent years.
CEO Transition – as previously reported on April 18, 2024, Eric Esser , President, and COO of Telesis Bio assumed the role of CEO and joined the Company’s Board of Directors. Prior to his appointment as CEO, Eric had successfully run Telesis Bio’s operations for approximately two years.
Pfizer Collaboration - in other recent highlights, the Company continues to pursue activities under its strategic research collaboration and license agreement with Pfizer. This program is based upon Telesis’ proprietary SOLA platform which utilizes enzymatic DNA synthesis technology for potential application by Pfizer in mRNA-based vaccines and other biopharma products.

 


 

 

Summary of Second Quarter 2024 Financial Results

Revenue - Revenue for the three months ended June 30, 2024 was $1.6 million compared to $7.0 million for the three months ended June 30, 2023 ($2.7 million and $8.7 million, respectively including revenue from Eton). The decrease was attributable to a reduction in product revenue of $1.8 million driven by our transition to Gibson SOLA as our primary commercial focus, and a decrease in collaboration revenue of $3.5 million, driven primarily by the timing of milestone completion under our strategic collaborations with Pfizer and reduction in deferred revenue recognition from up-front payments under that collaboration.

Gross Margin – The Company’s gross margin percentage was -52% for the three months ended June 30, 2024, compared to 71% for the same period in 2023. The unfavorable change in gross margin percentage was primarily driven by recognition of $1.8 million in one-time charges related to restructuring, and a decrease in high-margin collaboration revenue due to milestone timing. Absent the $1.8 million restructuring charge in the second quarter of 2024, gross margin would have been 64% for the quarter.

Operating Expense – Second quarter of 2024 operating expense of $10.7 million was $1.7 million or 14% improved from the prior year result of $12.4 million even with significant restructuring charges recorded during the current year period. Exclusive of employee severance and impairment charges tied to restructuring activity, the current year expense level of $10.7 million would have been $8.8 million representing a $3.7 million or 30% reduction from the prior year level of $12.4 million.

With respect to all restructuring charges noted above and posted in the second quarter of 2024, the favorable impact on future quarters will be substantial.

Net loss was $13.2 million for the second quarter of 2024, compared to a loss of $8.4 million in the same period in the prior year. Net loss per share was $7.62 for the second quarter of 2024, compared to $5.10 for the corresponding prior year period.

As of June 30, 2024, cash, cash equivalents, restricted cash, and investments were $10.3 million, and notes payable was $5.3 million.

The Company will not be issuing additional forward-looking guidance at this time.

 

About Telesis Bio

Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. Company products and technologies deliver virtually

 


 

error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com. Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

 

Contact:

William J. Kullback

Chief Financial Officer

bill.kullback@telesisbio.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

Telesis Bio Inc.

Selected Statements of Operations Financial Data

(in thousands, except per share amounts)

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

$

841

 

 

$

2,670

 

 

$

2,105

 

 

$

5,671

 

 

Service revenue

 

 

 

 

65

 

 

 

 

 

 

101

 

 

Collaboration revenue

 

 

 

 

3,462

 

 

 

 

 

 

4,424

 

 

Royalties and other revenue

 

709

 

 

 

807

 

 

 

1,634

 

 

 

1,486

 

 

Total revenue

 

1,550

 

 

 

7,004

 

 

 

3,739

 

 

 

11,682

 

 

Cost of revenue

 

2,349

 

 

 

2,039

 

 

 

3,431

 

 

 

3,934

 

 

Gross Profit

 

(799

)

 

 

4,965

 

 

 

308

 

 

 

7,748

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

2,470

 

 

 

3,921

 

 

 

4,829

 

 

 

8,414

 

 

Sales and marketing

 

1,698

 

 

 

3,192

 

 

 

3,260

 

 

 

6,867

 

 

General and administrative

 

5,507

 

 

 

5,294

 

 

 

10,481

 

 

 

10,396

 

 

Impairment of property and equipment

 

1,017

 

 

 

 

 

 

1,017

 

 

 

 

 

Total operating expenses

 

10,692

 

 

 

12,407

 

 

 

19,587

 

 

 

25,677

 

 

Loss from operations

 

(11,491

)

 

 

(7,442

)

 

 

(19,279

)

 

 

(17,929

)

 

Interest income

 

160

 

 

 

374

 

 

 

388

 

 

 

764

 

 

Interest expense

 

(214

)

 

 

(707

)

 

 

(431

)

 

 

(1,346

)

 

Change in fair value of derivative liabilities

 

 

 

 

19

 

 

 

 

 

 

159

 

 

Other expense, net

 

(15

)

 

 

(3

)

 

 

(146

)

 

 

(39

)

 

Provision for income taxes

 

(1

)

 

 

(4

)

 

 

(3

)

 

 

(7

)

 

Loss from continuing operations

 

(11,561

)

 

 

(7,763

)

 

 

(19,471

)

 

 

(18,398

)

 

Loss from discontinuing operations

 

(1,024

)

 

 

(524

)

 

 

(1,751

)

 

 

(1,008

)

 

Net Loss

$

(12,585

)

 

$

(8,287

)

 

$

(21,222

)

 

$

(19,406

)

 

Less: redeemable convertible preferred stock dividends

 

(596

)

 

 

(153

)

 

 

(1,181

)

 

 

(153

)

 

Net loss attributable to common stockholders

$

(13,181

)

 

$

(8,440

)

 

$

(22,403

)

 

$

(19,559

)

 

Net loss per share from continuing operations attributable to common stockholders—basic and diluted

$

(7.03

)

 

$

(4.79

)

 

$

(12.14

)

 

$

(11.24

)

 

Net loss per share from discontinuing operations attributable to common stockholders—basic and diluted

$

(0.59

)

 

$

(0.32

)

 

$

(1.03

)

 

$

(0.61

)

 

Net loss per share attributable to common stockholders—basic and diluted

$

(7.62

)

 

$

(5.10

)

 

$

(13.17

)

 

$

(11.85

)

 

Weighted average common stock outstanding—basic and diluted

 

1,730,210

 

 

 

1,654,127

 

 

 

1,700,596

 

 

 

1,651,053

 

 

 

 


 

Telesis Bio Inc.

Selected Balance Sheet Financial Data

(in thousands)

(unaudited)

 

 

 

June 30,

 

 

December 31,

 

 

2024

 

 

2023

 

Balance Sheet Data:

 

 

 

 

 

Cash, restricted cash, cash equivalents and short-term investments

$

10,314

 

 

$

19,333

 

Working capital

 

7,143

 

 

 

22,167

 

Total assets

 

52,727

 

 

 

70,411

 

Total liabilities

 

42,781

 

 

 

40,873

 

Redeemable convertible preferred stock

 

30,481

 

 

 

29,300

 

Accumulated deficit

 

(182,687

)

 

 

(161,465

)

Total stockholders’ (deficit) equity

 

(20,535

)

 

 

238

 

 

 

 

 

 

 

 


v3.24.2.u1
Document And Entity Information
Aug. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 07, 2024
Entity Registrant Name Telesis Bio Inc.
Entity Central Index Key 0001850079
Entity Emerging Growth Company true
Entity File Number 001-40497
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-1216839
Entity Address, Address Line One 10431 Wateridge Circle
Entity Address, Address Line Two Suite 150
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 228-4115
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TBIO
Security Exchange Name NASDAQ

Telesis Bio (NASDAQ:TBIO)
過去 株価チャート
から 10 2024 まで 11 2024 Telesis Bioのチャートをもっと見るにはこちらをクリック
Telesis Bio (NASDAQ:TBIO)
過去 株価チャート
から 11 2023 まで 11 2024 Telesis Bioのチャートをもっと見るにはこちらをクリック